Steven B Bradfute1, Ivy Hurwitz1, Alexandra V Yingling1, Chunyan Ye1, Qiuying Cheng1, Timothy P Noonan2, Jay S Raval3, Nestor R Sosa2, Gregory J Mertz1, Douglas J Perkins1, Michelle S Harkins4. 1. Center for Global Health, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. 2. Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. 3. Department of Pathology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA. 4. Division of Pulmonary, Critical Care and Sleep, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
Abstract
BACKGROUND: Convalescent plasma (CP) is a potentially important therapy for coronavirus disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers in donor plasma and their impact in patients with acute COVID-19 remains largely undetermined. We measured NAb titers in CP and in patients with acute COVID-19 before and after transfusion through the traditional Food and Drug Administration investigational new drug pathway. METHODS: We performed a single-arm interventional trial measuring NAb and total antibody titers before and after CP transfusion over a 14-day period in hospitalized patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection. RESULTS: NAb titers in the donor CP units were low (<1:40 to 1:160) and had no effect on recipient neutralizing activity 1 day after transfusion. NAb titers were detected in 6 of 12 patients on enrollment and in 11 of 12 at ≥2 time points. Average titers peaked on day 7 and declined toward day 14 (P = .004). Nab titers and immunoglobulin G levels were correlated in donor plasma units (ρ = 0.938; P < .001) and in the cumulative patient measures (ρ = 0.781; P < .001). CONCLUSIONS: CP infusion did not alter recipient NAb titers. Prescreening of CP may be necessary for selecting donors with high titers of neutralizing activity for infusion into patients with COVID-19. CLINICAL TRIALS REGISTRATION: NCT04434131.
BACKGROUND: Convalescent plasma (CP) is a potentially important therapy for coronavirus disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers in donor plasma and their impact in patients with acute COVID-19 remains largely undetermined. We measured NAb titers in CP and in patients with acute COVID-19 before and after transfusion through the traditional Food and Drug Administration investigational new drug pathway. METHODS: We performed a single-arm interventional trial measuring NAb and total antibody titers before and after CP transfusion over a 14-day period in hospitalized patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection. RESULTS: NAb titers in the donor CP units were low (<1:40 to 1:160) and had no effect on recipient neutralizing activity 1 day after transfusion. NAb titers were detected in 6 of 12 patients on enrollment and in 11 of 12 at ≥2 time points. Average titers peaked on day 7 and declined toward day 14 (P = .004). Nab titers and immunoglobulin G levels were correlated in donor plasma units (ρ = 0.938; P < .001) and in the cumulative patient measures (ρ = 0.781; P < .001). CONCLUSIONS: CP infusion did not alter recipient NAb titers. Prescreening of CP may be necessary for selecting donors with high titers of neutralizing activity for infusion into patients with COVID-19. CLINICAL TRIALS REGISTRATION: NCT04434131.
Authors: Nileena Velappan; Hau B Nguyen; Sofiya Micheva-Viteva; Daniel Bedinger; Chunyan Ye; Betty Mangadu; Austin J Watts; Robert Meagher; Steven Bradfute; Bin Hu; Geoffrey S Waldo; Antonietta M Lillo Journal: Bioengineered Date: 2022-05 Impact factor: 6.832
Authors: Paola de Candia; Francesco Prattichizzo; Silvia Garavelli; Rosalba La Grotta; Annunziata De Rosa; Agostina Pontarelli; Roberto Parrella; Antonio Ceriello; Giuseppe Matarese Journal: iScience Date: 2021-07-22
Authors: Adi V Gundlapalli; Reynolds M Salerno; John T Brooks; Francisco Averhoff; Lyle R Petersen; L Clifford McDonald; Michael F Iademarco Journal: Open Forum Infect Dis Date: 2020-11-17 Impact factor: 3.835
Authors: Leah Huey; Gillian Andersen; Patricia A Merkel; Thomas E Morrison; Mary McCarthy; Melkon G DomBourian; Kyle Annen; Erica D Dawson; Kathy L Rowlen; Vijaya Knight Journal: J Immunol Methods Date: 2021-07-22 Impact factor: 2.303